Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRNE exchanges : Nasdaq save search
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: -0.66%
H: 10.33%
C: 7.33%
SRNE | $0.015 56K
|
Health Technology
|
| O: -11.11%
H: 12.5%
C: 0.0%
company
Virpax Pharmaceuticals Reports 2023 Year-End Results
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
VRPX | $3.16 1.1K
|
|
| O: -0.68%
H: 3.17%
C: 2.65%
SRNE | $0.015 56K
|
Health Technology
|
| O: 11.11%
H: 0.0%
C: -10.0%
virpax pharmaceuticals results
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 0.72%
H: 2.89%
C: -2.14%
SRNE | $0.015 56K
|
Health Technology
|
| O: -7.14%
H: 46.15%
C: 38.46%
virpax wholly pharmaceuticals agreement
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Published: 2024-03-02 (Crawled : 00:20) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
| Email alert
Add to watchlist
SRNE | $0.015 56K
|
Health Technology
| Email alert
Add to watchlist
company
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Published: 2024-02-27 (Crawled : 13:30) - biospace.com/
VRPX | $3.16 1.1K
|
|
| O: -14.39%
H: 7.35%
C: -0.24%
SRNE | $0.015 56K
|
Health Technology
|
| O: 7.14%
H: 66.67%
C: -11.0%
virpax pharmaceuticals
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Published: 2024-02-26 (Crawled : 22:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 1.45%
H: 15.24%
C: 10.0%
SRNE | $0.015 56K
|
Health Technology
|
| O: 7.14%
H: 66.67%
C: -11.0%
virpax wholly pharmaceuticals agreement
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE | News 4 | $26.21 -0.42% 5M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | News | $98.03 0.77% 650K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE | $0.015 56K
|
Health Technology
|
| O: -63.33%
H: 263.64%
C: 127.27%
GILD | $66.85 -0.27% 1M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.475 -0.11% 41K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 3.82%
H: 5.76%
C: 1.04%
SRNE | $0.015 56K
|
Health Technology
|
| O: -2.03%
H: 3.42%
C: -1.08%
company
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Published: 2023-11-17 (Crawled : 17:00) - biospace.com/
VRPX | $3.16 1.1K
|
|
| O: 6.92%
H: 0.0%
C: -7.88%
SRNE | $0.015 56K
|
Health Technology
|
| O: 0.0%
H: 14.29%
C: 3.05%
nasdaq virpax pharmaceuticals
UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27 (Crawled : 20:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
| Email alert
Add to watchlist
SRNE | $0.015 56K
|
Health Technology
| Email alert
Add to watchlist
company update order
Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27 (Crawled : 18:00) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
| Email alert
Add to watchlist
SCLX | $0.92 -5.81% 370K
|
| Email alert
Add to watchlist
company order
Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price
Published: 2023-10-07 (Crawled : 00:20) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
| Email alert
Add to watchlist
SRNE | $0.015 56K
|
Health Technology
| Email alert
Add to watchlist
company program potential market
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company
Published: 2023-10-04 (Crawled : 17:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: -1.59%
H: 14.52%
C: 13.71%
SRNE | $0.015 56K
|
Health Technology
|
| O: -2.26%
H: 8.8%
C: 1.87%
company
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
Published: 2023-10-03 (Crawled : 13:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: -0.75%
H: 0.42%
C: -4.55%
SRNE | $0.015 56K
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -6.06%
company
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Published: 2023-09-22 (Crawled : 20:00) - biospace.com/
SCLX | $0.92 -5.81% 370K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.015 56K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP A | $2.32 -1.28% 4.5K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Published: 2023-09-21 (Crawled : 20:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.015 56K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP A | $2.32 -1.28% 4.5K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)
Published: 2023-09-14 (Crawled : 13:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 0.9%
H: 2.22%
C: -0.44%
SRNE | $0.015 56K
|
Health Technology
|
| O: -0.43%
H: 4.35%
C: 0.0%
sp-103 ztlido back trial
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Published: 2023-09-13 (Crawled : 13:00) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 1.23%
H: 0.0%
C: -9.72%
SRNE | $0.015 56K
|
Health Technology
|
| O: -6.99%
H: 39.83%
C: 33.53%
ORMP A | $2.32 -1.28% 4.5K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: -6.17%
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SCLX | $0.92 -5.81% 370K
|
|
| O: 2.49%
H: 2.83%
C: -1.21%
SRNE | $0.015 56K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
conference ztlido
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.